Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching

Liu Chaohua, Fei Xu, Wu Yutuan, Jiana Li, Ni Mengdong, Siyu Xia, Lihua Chen, Zhao Haiyun, Min Yu, Yuqi Zhou, Meiqin Zhang, Jiajia Li, Xiaohua Wu, Yan Huang, Tao Zhu, Xiaojun ChenProtein 2025 · DOI

TL;DR

Researchers have identified a novel strategy to overcome resistance to PARP inhibitors (PARPi) in ovarian cancer by targeting the kinase CLK1. Inhibiting CLK1 restores sensitivity to PARPi by altering the splicing of the ERCC1 gene, which is crucial for DNA repair, leading to increased DNA damage and cancer cell death. This discovery offers a promising new therapeutic avenue for patients with PARPi-resistant ovarian cancer.

What Problem Does This Paper Address?

Epithelial ovarian cancer (EOC) is a deadly disease with limited treatment options. While PARP inhibitors (PARPi) have revolutionized treatment, particularly for BRCA-mutant patients, a significant challenge is the development of resistance to these drugs. This resistance limits their long-term effectiveness, leaving patients with few alternatives. The paper aims to identify new therapeutic targets that can overcome this PARPi resistance, specifically in the context of ovarian cancer.

Methods

The study employed a multi-pronged approach:

  • Genome-wide CRISPR-Cas9 Knockout Screen: This high-throughput genetic screening method was used to identify genes whose depletion (knockout) confers sensitivity to PARPi in ovarian cancer cells. This involved infecting OVCAR8 cells with a CRISPR library and then treating them with a PARPi (Olaparib) or a control. By sequencing the sgRNAs present at different time points, researchers could identify genes that were essential for survival in the presence of the PARPi (dropout genes), indicating a role in resistance.
  • Kinase Drug Screening: Following the CRISPR screen, the researchers focused on genes encoding kinases for which clinically available inhibitors exist. They tested combinations of PARPi with inhibitors of these kinases in drug-resistant ovarian cancer cell lines.
  • Functional Validation: Promising candidates from the drug screen were further validated using various assays, including cell viability (CCK8), apoptosis (flow cytometry, Western blot), and colony formation assays.
  • In Vivo Studies: The efficacy of the identified therapeutic strategy was tested in mouse xenograft models of PARPi-resistant ovarian cancer.
  • Mechanistic Studies: To understand how CLK1 inhibition restores PARPi sensitivity, the researchers performed transcriptome sequencing, alternative splicing analysis (using rMATS), and investigated the interaction between CLK1, SRSF5, and ERCC1.

Datasets

The study utilized established ovarian cancer cell lines, including OVCAR8, SKOV3, A2780, TOV112D, OVCAR5, OVCA420, OVCA429, OVCA433, HEYA8, and HEY. They also generated PARPi-resistant cell lines (R8 OlaR and UWB1.289 OlaR) and used clinical samples of high-grade serous ovarian carcinoma for prognostic analysis.

Key Insights and Ideas

  • CLK1 as a Novel Target for PARPi Resistance: The most significant insight is the identification of CLK1 as a key player in PARPi resistance. Its inhibition, either genetically or pharmacologically, can re-sensitize resistant ovarian cancer cells to PARPi.
  • CLK1's Role in Alternative Splicing of ERCC1: The study uncovered a novel mechanism where CLK1 regulates the alternative splicing of the DNA repair gene ERCC1. Specifically, CLK1 promotes the expression of the functional ERCC1-202 isoform.
  • ERCC1-202 Isoform is Crucial for PARPi Resistance: The ERCC1-202 isoform is essential for forming a functional complex with XPF, which is critical for DNA repair. By downregulating this specific isoform, CLK1 inhibition impairs DNA repair, making cancer cells more vulnerable to PARPi.
  • CLK1/SRSF5 Axis Mediates ERCC1 Splicing: The research further elucidated that CLK1 acts through the SR protein family member SRSF5 to mediate the aberrant splicing of ERCC1.
  • Broader Applicability Beyond BRCA Status: The findings suggest that CLK1's role in PARPi resistance is independent of BRCA mutation status, potentially expanding the utility of PARPi in a wider patient population.

Key Results

  • A genome-wide CRISPR-Cas9 screen identified CLK1 as a top candidate gene whose loss confers PARPi sensitivity.
  • Combining the PARPi Olaparib with the CLK1 inhibitor TG003 showed potent anti-proliferative effects both in vitro and in vivo.
  • In PARPi-resistant ovarian cancer cells, CLK1 knockdown significantly increased apoptosis and reduced colony formation upon Olaparib treatment.
  • In vivo studies demonstrated that CLK1 inhibition in combination with Olaparib significantly reduced tumor growth and volume in mice.
  • Mechanistically, CLK1 inhibition led to decreased expression of the ERCC1-202 isoform, impaired DNA repair (indicated by increased γ-H2AX and RAD51), and enhanced apoptosis.
  • Clinical data suggested a correlation between higher CLK1 expression and reduced overall survival in ovarian cancer patients.

Limitations and Future Work

  • Technical Challenges with ERCC1 Isoform Detection: The study notes a significant limitation in the current lack of commercially available antibodies that can specifically detect the ERCC1-202 isoform without cross-reactivity. This hinders reliable IHC assessment of ERCC1-202 in clinical samples and its translation into a biomarker.
  • Need for Larger Clinical Validation: While promising, the findings regarding CLK1's prognostic value in clinical samples require further validation in larger, well-annotated patient cohorts.
  • Exploration of Other Synthetic Lethal Candidates: The CRISPR screen identified other potential synthetic lethal candidates, which warrant further investigation for their roles in PARPi resistance and as therapeutic targets.
  • Immunomodulatory Potential: The study hints at CLK1 inhibition potentially augmenting PARPi efficacy via immune modulation, which is an exciting area for future research.
  • Predictive Biomarker Development: The authors suggest that components of the CLK1-SRSF5-ERCC1 axis could serve as predictive biomarkers for guiding patient selection and optimizing PARPi-based therapies, pending further development and validation.

Summary updated

Abstract

Epithelial ovarian cancer (EOC) is an aggressive malignancy with limited therapeutic options. Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown remarkable efficacy, especially in BRCA-mutant patients, and are approved as maintenance therapy to prevent recurrence after initial response to chemotherapy. However, the development of PARPi resistance poses a major clinical challenge. This study utilized a whole-genome CRISPR-Cas9 genetic screening to identify genes associated with PARPi sensitivity upon knockout. Based on the screening and validated through further experiments, we confirmed that CLK1 knockdown is synthetically lethal with PARPi in ovarian cancer. The combination of the PARPi Olaparib and CLK1 inhibitor TG003 exhibited potent anti-proliferative effects both in vitro and in vivo. Mechanistically, CLK1 inhibition downregulated the functional ERCC1-202 isoform, resulting in enhanced DNA damage and apoptosis. Our findings reveal a novel mechanism underlying PARPi sensitivity and suggest that targeting CLK1 in combination with PARPi may represent a promising therapeutic strategy for PARPi-resistant ovarian cancer.
BibTeX
@inproceedings{chaohua2025genome,
  author = {Liu Chaohua and Fei Xu and Wu Yutuan and Jiana Li and Ni Mengdong and Siyu Xia and Lihua Chen and Zhao Haiyun and Min Yu and Yuqi Zhou and Meiqin Zhang and Jiajia Li and Xiaohua Wu and Yan Huang and Tao Zhu and Xiaojun Chen},
  title = {{Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching}},
  booktitle = {Protein},
  year = {2025},
  doi = {10.1093/procel/pwaf091},
}
Figure